The Foundation for Cancer Research Support (RakFond)
About the Foundation
The Foundation for Cancer Research Support (RakFond) is a non-profit organization with the main objectives of:
- funding R&D activities and the development of new methods and tools for the prevention, diagnosis and treatment of cancer;
- promoting the advancement of research activities of scientific institutions, centers, oncological hospitals, and individual specialists in the field of oncology.
The Foundation was founded in 2017 and operates in the Russian Federation.Support our Work! RakFond’s Strategy
Articles and Reviews
- ANNUAL CANCER PROGRESS REPORT ISSUED BY THE AMERICAN ASSOCIATION FOR CANCER RESEARCHDISCOVERY SCIENCE DRIVING CLINICAL BREAKTHROUGHS The American Association for Cancer Research (AACR) released its annual Cancer Progress Report, which highlights advances over the past 12 months in the prevention, detection, […]
- ASCO’s Clinical Cancer Advances 2021 ReportASCO’s Clinical Cancer Advances annual report highlights current trends in the field and identifies cancer research priorities that have great potential to advance progress against cancer. The 16th edition of […]
- CHRONOS19 WILL BE PRESENTED AT THE EHA 2021 VIRTUAL CONGRESSThe results of the subgroup analysis of the CHRONOS19 registry in patients with acute leukemia and COVID-19 will be presented orally by the study PI Olga Gavrilina, MD, PhD, at […]
- Bright scientific events in oncology in 2020Author: Alexey Tikhonov 2020 was marked by a large number of striking events in the oncology field, and in this material, I would like to highlight a number of studies […]
- CHRONOS19: INTERIM ANALYSIS OF THE OBSERVATIONAL STUDY OF COVID-19 IN PATIENTS WITH BLOOD DISEASESThe emergence of a new infectious disease COVID-19 led to the extensive research of not only the coronavirus itself, but also the course of this disease in different patient populations. […]
- Loss of Heterozygosity in the Short Tandem Repeat (STR) Loci Found in Tumor DNA of De Novo Diagnosed ALL Patients As a Factor Predicting Poor Outcome: Interim Results Of The StudyThis study was supported by RakFond, Grant No. 5/2019 KEY WORDS: Loss of heterozygosity (LOH), de novo diagnosed ALL, chromosome aberration, hidden chromosomal abnormalities, uniparental disomy Introduction Acute lymphoblastic leukemia […]
- PLATINUM-BASED CHEMOTHERAPY IN TREATMENT OF PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCEROvarian cancer is one of the most sensitive tumors to chemotherapy – in most cases it is possible to achieve complete tumor regression affected by modern drug treatment. Unfortunately, despite […]
- Annual cancer progress report issued by the American association for cancer researchTurning science into lifesaving care The American Association for Cancer Research (AACR) released its annual Cancer Progress Report, which highlights advances over the past year in the prevention, detection, diagnosis, […]
- Highlights of 2020 ASCO Annual MeetingThis year the American Society of Clinical Oncology (ASCO) Annual Meeting was delivered in a new virtual format on May 29-31, 2020 with a record-breaking attendance of more than 42,700 […]
Interviews with Experts
RakFond’s experts talk in their short interviews about their choice to become an oncologist, which cancer research they could name as their favorite, and why cancer research support is important.
Interview with Tatiana Semiglazova, MD, DSci, Professor, Head of Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N.N. Petrov National Medical Research Center of Oncology (St. Petersburg, Russia), Professor at the Department of Oncology, I.I. Mechnikov North-Western State Medical University (St. Petersburg, Russia), Board member of the Russian Society of Clinical Oncology (RUSSCO), Member of RakFond’s Scientific Advisory Board.The topic of the interview is the rehabilitation of cancer patients. Learn more about physical, metabolic, and psychological rehabilitation, and how it affects the outcomes of cancer patients treatment.
Interview with Andrei Gudkov, Ph.D., D.Sci., Senior Vice President, Research Technology and Innovation, Chair, Cell Stress Biology, Roswell Park Comprehensive Cancer Center (Buffalo, USA), Member of RakFond’s Scientific Advisory Board.
Learn about the relationship between cancer and evolution, what the scientists may be proud of, and where the curiosity leads us.
Interview with Katerina Gurova, M.D., Ph.D., Professor of Oncology, Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center (Buffalo, USA), Member of RakFond’s Scientific Advisory Board.
Learn about the regulation of reading in the library of genes, the role of the “gene of conscience” in carcinogenesis and how we can learn to control cancer.
Interview with Jacek Gronwald, PhD, Professor, Department of Genetics and Pathology, Pomeranian Medical University (Szczecin, Poland), Member of RakFond’s Scientific Advisory Board.
Learn about hereditary cancers, studies of lifestyle factors in oncology, and why every research is some kind of a startup.
Interview with Alexey Danilov, Associate Professor of Medicine, Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University (Portland, USA), Member of RakFond’s Scientific Advisory Board.
Learn about research translation from bench to bedside, the discovery and research of the novel therapies in hematologic malignancies, the support of research initiatives by private foundations and how to see the diagnosis with one’s own eyes.
Interview with Alexey Tryakin, M.D., D.Sci., Chief Scientist, Department of Clinical Pharmacology and Chemotherapy of N.N. Blokhin National Medical Research Center of Oncology (Moscow, Russia), ESMO National Representative in the Russian Federation, Board member of the Russian Society of Clinical Oncology (RUSSCO), Member of RakFond’s Scientific Advisory Board.
Learn about the inception of the targeted therapy in oncology, what advantages of participating in clinical trials bring to doctors and patients in Russia, and why there should be even more research.